X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ALEMBIC PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ALEMBIC PHARMA PFIZER/
ALEMBIC PHARMA
 
P/E (TTM) x 28.6 28.2 101.4% View Chart
P/BV x 4.5 6.4 70.7% View Chart
Dividend Yield % 0.7 0.7 97.3%  

Financials

 PFIZER   ALEMBIC PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
ALEMBIC PHARMA
Mar-16
PFIZER/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs2,724792 344.1%   
Low Rs1,611443 363.7%   
Sales per share (Unadj.) Rs440.9167.0 264.0%  
Earnings per share (Unadj.) Rs48.738.2 127.6%  
Cash flow per share (Unadj.) Rs75.842.0 180.4%  
Dividends per share (Unadj.) Rs15.004.00 375.0%  
Dividend yield (eoy) %0.70.6 106.8%  
Book value per share (Unadj.) Rs462.984.9 545.3%  
Shares outstanding (eoy) m45.75188.52 24.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.7 133.0%   
Avg P/E ratio x44.516.2 275.2%  
P/CF ratio (eoy) x28.614.7 194.6%  
Price / Book Value ratio x4.77.3 64.4%  
Dividend payout %30.810.5 293.9%   
Avg Mkt Cap Rs m99,163116,383 85.2%   
No. of employees `0002.9NA-   
Total wages/salary Rs m2,7584,214 65.4%   
Avg. sales/employee Rs Th6,981.7NM-  
Avg. wages/employee Rs Th954.5NM-  
Avg. net profit/employee Rs Th771.1NM-  
INCOME DATA
Net Sales Rs m20,17031,487 64.1%  
Other income Rs m85755 1,556.1%   
Total revenues Rs m21,02831,542 66.7%   
Gross profit Rs m4,31010,060 42.8%  
Depreciation Rs m1,239722 171.5%   
Interest Rs m537 14.1%   
Profit before tax Rs m3,9239,356 41.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7942,160 83.1%   
Profit after tax Rs m2,2287,194 31.0%  
Gross profit margin %21.431.9 66.9%  
Effective tax rate %45.723.1 198.1%   
Net profit margin %11.022.8 48.3%  
BALANCE SHEET DATA
Current assets Rs m16,29915,066 108.2%   
Current liabilities Rs m7,5947,674 98.9%   
Net working cap to sales %43.223.5 183.8%  
Current ratio x2.12.0 109.3%  
Inventory Days Days6567 97.5%  
Debtors Days Days2641 63.4%  
Net fixed assets Rs m8,6228,237 104.7%   
Share capital Rs m458377 121.4%   
"Free" reserves Rs m20,72215,416 134.4%   
Net worth Rs m21,18016,005 132.3%   
Long term debt Rs m250-   
Total assets Rs m29,13724,594 118.5%  
Interest coverage x755.5255.2 296.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.3 54.1%   
Return on assets %7.729.4 26.1%  
Return on equity %10.544.9 23.4%  
Return on capital %19.058.7 32.4%  
Exports to sales %0.155.7 0.1%   
Imports to sales %17.510.4 167.6%   
Exports (fob) Rs m1217,551 0.1%   
Imports (cif) Rs m3,5263,283 107.4%   
Fx inflow Rs m5217,811 0.3%   
Fx outflow Rs m1405,318 2.6%   
Net fx Rs m-8812,493 -0.7%   
CASH FLOW
From Operations Rs m3,4369,304 36.9%  
From Investments Rs m-6,991-3,105 225.2%  
From Financial Activity Rs m-619-1,959 31.6%  
Net Cashflow Rs m-4,1744,240 -98.4%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 2.9 258.6%  
FIIs % 4.9 9.1 53.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 13.9 170.5%  
Shareholders   85,207 49,328 172.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jan 24, 2018 09:29 AM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS